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ABSTRACT
Background: Allergic rhinitis represents a worldwide health problem. The prevalence is increasing. The aim
of this study was to analyse the correlation between the severity of allergic rhinitis and an adequate treatment
dose of modern oral antihistamines.
Methods: From a comprehensive databank containing data from ten different open-label prospective observa-
tional studies including raw data of 140,853 patients with allergic rhinitis, symptomatology variables were ana-
lysed and scored to study the effects of treatment with four antihistamines (Desloratadine, Ebastine, Fexofena-
dine, Levocetirizine) alone or in combination with intranasal corticosteroids. The patient data were collected in
23,606 study centres from Germany, mostly medical specialist and some primary care physicians in private
practice. The analyses were performed via individual patient data meta-analysis techniques.
Results: Finally 92,900 patient data from nine of ten studies could be analysed. One study with data of 47,953
patients was excluded due to incomplete treatment documentation. Both monotherapy analysis subgroups (To-
tal Symptom Score and Total Nasal Symptom Score) were significantly better than those of their combinations
with intranasal steroids. Monotherapy with levocetirizine was determined to be significantly more effective in
lowering the Total Symptom Score (p < 0.001) and the Total Nasal Symptom Score (p < 0.05) than the other
antihistamines. In the next stage, a greater positive effect of levocetirizine was demonstrated in relation to the
severity of the clinical symptoms of allergic rhinitis (Total Nasal Symptom Score in cases with severe sympto-
matology [effect size = -0.09]).
Conclusions: Levocetirizine asserted itself as the only antihistamine compared with the others as significant
in this analysis. The study authors recommend monotherapy with the new-generation antihistamine levocetiriz-
ine, especially in severe cases of allergic rhinitis.
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INTRODUCTION
Allergic rhinitis is considered the most significant
atopic condition, affecting 65 million people in the
United States alone.1 Its estimated prevalence in cen-
tral Europe shows that the disease affects 17 to 29% of
the population, and is rising.2 This rise needs to be
observed and documented in the different regions of
the world so that investigational results can be used
to represent and indicate international rather than re-
gional findings.2-8
Today’s antiallergic therapy is based upon three
measures: avoidance or elimination of the causative
agent (allergen), anti-symptomatic pharmacotherapy,
and specific immunotherapy. Along with intranasal
corticosteroids, leukotriene receptor antagonists9 and
mast cell stabilizers, modern, new-generation antihis-
tamines are the pillars of the pharmaceutical compo-
nent in the management of allergic rhinitis.
International guidelines recommend modern oral
antihistamines for first-line treatment of allergic rhini-
tis and conjunctivitis in adults and children. The most
effective treatment for allergic rhinitis are the intrana-
sal corticosteroids; however, no sufficient data are
available that supports the combined use of these two
medications. Broadly speaking, each new patient
should be considered and managed differently ac-
cording to the duration and severity of the clinical pic-
ture, the patient’s personal preferences, the accessi-
bility and affordability of medications, and the suc-
cess and effectiveness of a therapeutic option applied
in the patient’s particular case.10
Similar findings were presented by Benninger et
al.,11 who evaluated the impact of medications in the
treatment of allergic rhinitis in the United States on
nasal symptoms. An evidenced based review was con-
ducted with finally 54 randomized, placebo controlled
studies. The findings reveal that the treatment with
intranasal steroids shows the greatest improvements
for nasal symptoms. Regarding our analysis, the
equal effectiveness for some patients treated with oral
antihistamines is of special interest.
In this analysis, we have examined the effect of pre-
scribing a less intricate, yet possibly more effective
therapy for lowering the symptom score in allergic
rhinitis: using modern antihistamines alone rather
than the traditional combination of antihistamines
and intranasal steroids. First tendencies and descrip-
tions of this data pool on comparison between these
two treatment options are already published by Mos-
ges.12
METHODS
OBJECTIVES AND STUDY DESIGN
At the Institute of Medical Statistics, Informatics and
Epidemiology (IMSIE), University of Cologne, Ger-
many, we pooled and analysed already existing data
from 140,853 patients with the clinical diagnosis of al-
lergic rhinitis that had been collected from ten open-
label prospective observational studies conducted be-
tween 1998 and 2005 by pharmaceutical companies.
All studies on the four different antihistamines
were funded and conducted by the companies them-
selves (DesloratadineEssex Pharma GmbH,
EbastineAlmirall Hermal GmbH, Fexofenadine
Sanofi-Aventis Deutschland GmbH, Levocetirizine
UCB Pharma GmbH). In our analysis we focused on
post-marketing studies, because of their practical de-
sign. The analysed antihistamines are from the mod-
ern generation and belong to well-established pre-
scription medications at the time of examination. We
received all observational studies on allergic rhinitis
by the enterprises mentioned above. Besides, all in-
vestigations were released. The data were obtained
via paper-based Case Report Forms, which were filled
in by the investigators during the patients’ visit at
their practice. They were then transcribed into data-
bases by the pharmaceutical companies.
We previously published observational studies con-
ducted with azelastine for the treatment of allergic
rhinitis.13,14 Those were not included as the route of
application (nasal spray) differs from the other stud-
ies and this probably has a major impact on compli-
ance and consequently effectiveness.
Our examination compares a single monotherapy
with levocetirizine against its combination with in-
tranasal corticosteroids and against the same specific
effects of other new generation antihistamines.
An overview about the different study designs and
the various investigation scores is given in Table 1.
The nasal and eye symptoms which we included in
the analysis were summarized to TNSS (including:
nasal obstruction, secretion, sneezing and itching)
and Total Ocular Symptom Score (TOSS) (including:
tearing, itchingburning, redness), as far as possible,
according to the availability of data about these vari-
ables. The baseline score (first screening) was as-
sessed with patients who have not taken any study
medication. The interval between baseline and end-
point score amounts to four weeks in all studies.
The data collected were used to compare the ef-
fects of levocetirizine 5 mg tablets with those of
either ebastine (2 × 10 mg, 1 × 20 mg), desloratadine
(5 mg) or fexofenadine (120 mg) alone or in combina-
tion with intranasal corticosteroids. The effectiveness
of administering the various antihistamines as mono-
therapy was then analysed further. This could be
done by comparing each single nasal symptom score
after their administration. In this stage, however, it
was necessary to identify data from the 10 studies
and extract a sufficient amount of relevant and valid
information from them about the nasal symptoms
which could then be used in the correlation process.
The individual symptoms constituting the symptom
scores, such as “sneezing and itching”, “secretion”
and “obstruction” were then grouped and classified
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Table　1　Overview: ten open-label prospective observational studies
Deslorata-
dine 
(Feb. 2001-
Sep. 2001)
Desloratadine 
(Dec. 2001-
Mar. 2002)
Desloratadine 
(Mar. 2001-
May 2002)
Ebastine 
(Apr. 2002-
Aug. 2004)
Ebastine 
(Mar. 2004-
Sep. 2005)
Levocetirizine 
(Jan. 2001-
Sep. 2001)
Fexofenadine 
(4 studies from 
Jan. 1998-
Aug. 2001)
Study data:
Patients adults:
≥18 years
adults:
≥18 years
children:
≥12 years
adults:
≥18 years
children:
≥12 years
adults:
≥18 years
children:
≥12 years
adults:
≥18 years
children:
≥12 years
adults:
≥18 years
children:
≥12 years
adults:
≥18 years
children:
≥12 years
Duration
/
Dose
6 weeks, 
2 visits
/
5 mg daily
4 weeks, 
2 visits
/
5 mg daily
4 weeks, 
2 visits
/
5 mg daily
4 weeks, 
2 visits
/
20 mg daily 
(2 × 10 mg)
4 weeks, 
2 visits
/
20 mg daily 
(1 × 20 mg)
4 weeks, 
3 visits
/
5 mg daily
4 weeks, 
4 visits
/
120 mg
No. of patients/
Study centres
47,953/
10,000
7,498/
1,000
13,183/
3,506
4,704/
1,000
4,307/
1,000
17,678/
2,100
45,530/
5,000
Medical scores
nasal 
symptoms 
(sum score) 

obstruction       
secretion       
sneezing       
itching       
ocular 
symptoms 
(sum score) 
   
tearing  
itching/
burning
 
redness  
Baseline 
characteristics
Treatment 
regimen
AH AH + 
INS
AH AH + 
INS
AH AH + 
INS
AH AH + 
INS
AH AH + 
INS
AH AH + 
INS
AH AH + 
INS
No. of patients 
(with complete 
data)
-- -- 676 526 1581 354 818 569 535 318 3307 169 9000 995
Age (±SD) -- -- 38.0 
(±14.2)†
39.5 
(±14.3)
40.3 
(±14.7)
39.6 
(±13.6)
37.5 
(±14.8)
36.87 
(±13.3)
39.0 
(±15.1)
40.8 
(±13.9)
35.4 
(±13.9)
34.2 
(±12.9)
35.9 
(±13.2)†
36.8 
(±14.2)
TNSS (±SD) -- -- 7.5 
(±0.7)†
7.6 
(±0.7)
7.8 
(±0.8)†
7.9 
(±0.8)
7.9 
(±0.8)
7.7 
(±0.8)
7.8 
(±0.8)
7.9 
(±0.8)
7.8 
(±0.8)
7.8 
(±0.8)
7.8 
(±0.8)
7.8 
(±0.8)
Nasal obstruc-
tion (±SD)
-- -- 2.5 
(±0.6)†
2.8 
(±0.5)
2.5 
(±0.6)†
2.7 
(±0.5)
2.5 
(±0.6)†
2.7 
(±0.5)
2.4 
(±0.6)†
2.6 
(±0.6)
2.4 
(±0.7)†
2.6 
(±0.6)
2.5 
(±0.6)†
2.6 
(±0.6)
Total symptom 
score (±SD)
-- -- 2.5 
(±0.5)†
2.6 
(±0.5)
3.0 
(±0.5)
3.0 
(±0.5)
3.0 
(±0.5)
3.0 
(±0.5)
3.0 
(±0.5)
3.0 
(±0.5)
3.0 
(±0.5)
3.0 
(±0.5)
3.0 
(±0.5)
3.0 
(±0.5)
Intranasal 
steroids 
(Intake across 
all studies)
Mometason (Nasonex®) --> 60%
Fluticason (Flutide nasal) --> 20%
Triamcinolonacetonid - nasal spray (Nasacort®) --> 10%
Beclometason - nasal spray (Beconase® plus generics) --> 5%
Budesonid (Pulnicort nasal® plus generics) --> 5%
†signifi cant in comparison to AH + INS (p < 0.05).
Mösges R et al.
218 Allergology International Vol 62, No2, 2013 www.jsaweb.jp
into three categories of mild, moderate and severe
symptoms.
DATA CLEARANCE AND PLAUSIBILITY CHECK
The data sets were examined for plausibility and er-
rors. Whenever it was not possible to rectify the vari-
ables of a data set, missing values were assumed in-
stead. After controlling for plausibility, patient data
sets with less than 50% of all data necessary for calcu-
lation of analysis parameters were identified, in order
to be excluded from the final analysis file.
PATIENTS
All patients were at least twelve years old. The aver-
age age of the patients in the different studies was
36.11 up to 39.9 years. The gender distribution
showed a greater number of females (55.3%). In addi-
tion to the age and gender, the anamnesis of the pa-
tients was examined. All included patients declared at
the beginning of treatment that they were already af-
fected by allergic rhinitis for more than six years on
average. 31.7% of all study participants indicated that
they suffered for more than 10 years from this dis-
ease. There were no study differences in the median
of the severity in ocular or nasal symptoms at base-
line.
STATISTICS
The statistical calculations performed on the ex-
tracted data were conducted using the statistic soft-
ware SPSS version 20 and the Cochrane Collabora-
tion’s Review Manager 5.1 software.
The individual results of these studies had not yet
been published; thus, we speak here of a “pooled
analysis” or an “individual patient data (IPD) meta
analysis”. The analysis was realized via two method-
ologies. On the one hand the effect estimates were
calculated separately for each trial and then com-
bined using the meta-analysis techniques by Review
Manager. Therefore study-specific effects were calcu-
lated by weighted mean differences. The overall ef-
fect was estimated using the ‘inverse variance’
method. For homogeneous and heterogeneous study-
specific effects, the ‘fixed effects’ and ‘random effects’
models were used. On the other hand all data from
the studies were pooled to one “mega trial” to per-
form a single analysis with the statistic software
SPSS. Both analyses showed nearly the same results,
so that the random effect model was used to neutral-
ize possible bias.15,16
The data pool was examined and analyzed further
in order to obtain data on the effectiveness of therapy
for allergic rhinitis in these patients. Due to the diver-
sity of the available data, the number of subjects was
different for each sample taken from the various stud-
ies included in the evaluation process.
ETHICS
The data examined here were raised prospective
within the scope of not randomized not controlled ob-
servation studies. In Germany no approval by an ethi-
cal commission is needed, because here exclusively
the therapeutic care is documented. Information
about these regulations are published by the Federal
Institute for Drugs and Medical Devices in Germany.
However, all patients had to sign a privacy policy and
had agreed that their pseudonymized data can be
used for analysis. All patients who took part in the ob-
servation studies had delivered their written in-
formed consent, to the capture, storage and process-
ing of their pseudonymized data.
RESULTS
One of the three studies with desloratadine (47,953
patients) had to be excluded from the analysis due to
incomplete treatment documentation especially at the
items describing treatment modalities and symptoms,
which were essential to generate symptom scores.
Furthermore patients of this study showed a high
proportion of missing data and were excluded within
the analysis step “data clearance”.
The indirect statistical comparison of pooled data
from the selected treatment groups yields effect sizes
for each individual antihistamine when compared to
its combination with intranasal corticosteroids (Fig.
1, 2). The results were split in two groups “Levoceti-
rizine” and “Other antihistamines”, because the in-
vestigations proved no significant results between the
other subgroups tests. Levocetirizine asserted itself
as the only antihistamine that compared significantly
with the others as in this analysis. The negative sign
indicates a significantly more positive effect of the re-
spective monotherapy on patient symptom improve-
ment relative to that of use in combination with an in-
tranasal steroid.
Both monotherapy analysis subgroups were signifi-
cantly better than those of their combinations with in-
tranasal steroids. The largest effect size on both TSS
(including TNSS and TOSS) and TNSS was identified
for levocetirizine treatment. Despite the apparently
wider 95% confidence intervals for both scores (TNSS
= 0.27 and TSS = 0.1), levocetirizine proved to be sig-
nificantly more effective especially in reducing the to-
tal symptom scores (p < 0.001) compared to the medi-
cations in the subgroup “other antihistamines”. The
confidence intervals for the subgroup “other antihis-
tamines” were 0.06 for TNSS and 0.02 for TSS, dem-
onstrating a relatively high precision of results. The
numbers of subjects included in each of the analysis
subgroups, however, at 48,265 in the TNSS and
49,512 in the TSS groups receiving “other antihista-
mines” and 9,796 for the TNSS and 10,863 for the
TSS groups obtaining levocetirizine, were clearly
higher for the former group, thus possibly having
had an influence on the 95% confidence intervals and
Treatment of Allergic Rhinitis
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Fig.　1　TSS, monotherapy vs. combination therapy. Difference in effect size in to-
tal symptom score when comparing antihistamine monotherapy with the combina-
tion of the respective antihistamine (levocetirizine or any of the other antihista-
mines) plus application of an intranasal steroid. Signifi cance level = test for 
subgroup differences (“Levocetirizine” versus “Other antihistamines”).
0
-0.1
-0.2
-0.3
-0.4
p < 0.001
TSS
Levocetirizine Other antihistamines
-0.28Effect size -0.06
Fig.　2　TNSS, monotherapy vs. combination therapy. Difference in effect size in 
total nasal symptom score in favours of monotherapy when comparing antihista-
mine monotherapy with the combination of the respective antihistamine (levocetiri-
zine or any of the other antihistamines) plus application of an intranasal steroid. 
Signifi cance level = test for subgroup differences (“Levocetirizine” versus “Other 
antihistamines”).
p < 0.05
TNSS
0.1
0
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
-0.7
Levocetirizine Other antihistamines
-0.38Effect size -0.05
accounting for the broad levocetirizine confidence in-
terval.
Accordingly, TNSS could then be determined for
each subject, placing them in either the “mildmoder-
ate” or “severe” TNSS subgroups, whether the classi-
fication of allergic rhinitis according to ARIA is “mild”
and “moderatesevere”.10 The individual definition of
this scoring system is17:
Mild = signsymptom clearly present, but minimal
awareness; easily tolerated.
Moderate = definite awareness of signsymptom
that is bothersome but tolerable.
Severe = signsymptom that is hard to tolerate;
causes interference with activities of daily living and
or sleeping.
Figure 3 illustrates a trend towards effect because
of the greater numerical effectiveness of levocetiriz-
ine monotherapy in reducing the symptoms “moder-
ate obstruction” (mean effect = -0.04) and “severe ob-
struction” (mean effect = -0.07) compared to the
group of other antihistamines. The positive effect
from levocetirizine on the nasal symptom “obstruc-
tion” was already demonstrated in a meta-analysis.18
In addition, our results show the differentiation in se-
verity.
The effect for “other antihistamines” was taken as a
reference point (zero line) for comparison with the
results for levocetirizine effectivity. The number of
cases represents the total number of patients for both
groups. The negative sign of the effect size means
that levocetirizine has the greater positive effect
which, although possible to demonstrate here, was
not found to be statistically significant in any individ-
ual symptom subgroup. Further analysis of the data
Mösges R et al.
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Fig.　3　Nasal symptom “obstruction”-levocetirizine vs. other antihistamines. Difference in 
effect size in nasal symptom score “obstruction” when comparing levocetirizine with any of 
the other antihistamines as monotherapy. Number of cases = Number of included patients 
from all studies.
0.05
0
-0.05
-0.1
-0.15
-0.2
Effect size
Obstruction-mild
0
13,341
Obstruction-moderate
-0.04
25,051
Obstruction-severe
-0.07
10,237Number of cases
Fig.　4　TNSS-levocetirizine vs. other antihistamines. Difference in effect size in total na-
sal symptom score when comparing levocetirizine with any of the other antihistamines as 
monotherapy. Signifi cance level = test for subgroup differences (“TNSS-mild/moderate” 
versus “TNSS-severe”).
p < 0.01
TNSS-mild/moderate
0.19
36,244
TNSS-severe
-0.09
17,203
0.4
0.3
0.2
0.1
0
-0.1
-0.2
-0.3
-0.4
Effect size
Number of cases
pool for the individual symptom scores revealed that
the effect size increases proportionally with the in-
crease in severity of the scored symptoms. For these
results, the curve for the mean effect size on the indi-
vidual symptom scores is positively skewed to the
right. Upon overall examination of the total score for
severe nasal symptoms, levocetirizine was found to
have a numerically higher treatment success (effect
size -0.09), shown in Figure 4.
Assuming that the results for effect sizes and mean
differences for the whole study data arose merely be-
cause of random variation, it can be said that the ef-
fectiveness of levocetirizine treatment is better in the
case of severe nasal symptoms than in mild to moder-
ate ones (p < 0.01) although the confidence limit bars
slightly overlap (0.05).
DISCUSSION
The effectiveness of using newer antihistamines in
urticaria for severe allergic symptoms has been previ-
ously studied by Staevska, M. et al..19 In this study,
the doses of levocetirizine and desloratadine were
raised stepwise at certain intervals. Levocetirizine’s
ability to act as a “strong” modern antihistamine was
further underlined in these results.
In various investigations and studies the superior-
ity of new generation antihistamines compared with
placebo was proven. These findings were summa-
rized and discussed by creating systematic reviews
and meta-analysis for all antihistamines analysed
here.20-24 In the meta-analysis by Ratner, et al.23
ebastine was compared to loratadine, also an antihis-
tamine from the second generation for the systemic
use of allergic diseases. Here ebastine could show a
greater decrease in mean rhinitis score from baseline
over two and four weeks compared to loratadine and
placebo. In the publication by Holgate, et al.25 four
different published studies on levocetirizine were an-
alysed for meaningful outcome measures. The
authors support, that levocetirizine should be used
for short-term and long-term treatment of allergic
rhinitis. In particular the improvenment in quality of
life regarding long-term treatment is mentioned. Fur-
thermore levocetirizine improves the symptom score
after 24 hours compared to fexofenadine and des-
loratadine. Similar findings for the effectiveness of
levocetirizine are shown in the meta-analysis by Khi-
aney and Weinstein.22 Their data prove that levoceti-
rizine is highly effective in reducing the total symp-
tom score and the Rhinoconjunctivitis Quality of Life
Questionaire score.
Our pooled-analysis illustrates that levocetirizine is
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significantly more effective than other antihistamines
in symptom alleviation. As presented in the results of
this publication, the statistically proven overall advan-
tage of levocetirizine over the other antihistamines
could not be verified further in the subanalysis of its
effect on the various specific nasal symptom scores.
However, a clear tendency in the correlation between
symptom severity and levocetirizine drug effectivity
could be observed. This can clearly be demonstrated
for the symptom of nasal blockage, a major weakness
of the second generation antihistamines. The more
pronounced these symptoms are, the clearer the su-
periority of levocetirizine shows up. One may argue,
that the effect size of 0.07 is “less than small” accord-
ing to Cohen’s definition.26 However the contrast that
we observe in this investigation is not between pla-
cebo and an active drug as it is normally the case in
such meta-analyses but between well established
modern antihistamines of the latest generation. The
effect we find here is about half of the size reported
for the difference between a nasal steroid and second
generation antihistamine.27 Surprisingly, the effect of
levocetirizine alone in lowering nasal symptoms is
stronger than that of its combination with nasal ster-
oids. Similar findings have been described before.12
This effect has been attributed to reduced compli-
ances with a treatment scheme that includes two dif-
ferent routes of application, oral and local. For the al-
leviation of nasal blockage regular intake of medica-
tion is essential since other mediators than Histamine
are involved. Their down regulation requires continu-
ous intake as has been shown by Canonica, et al..28 In
this analysis we can demonstrate that the superiority
of antihistamine monotherapy is more pronounced
when the “strong” antihistamine levocetirizine is
used than when other modern antihistamines are pre-
scribed alone or in combination with intranasal corti-
costeroids.
Possible confounders that may have had an effect
on the reliability of this investigation’s results may in-
clude: variations in the number and age distribution
of subjects in the study subgroups, subjects’ concomi-
tant illnesses, patients’ compliance, degree of symp-
tom severity determined for initiating treatment, and
finally, study duration.
Since the study data lack homogeneity, we were
not able to demonstrate with statistical significance a
positive correlation between the alleviation of nasal
symptom severity and effective treatment with the ac-
tive substance levocetirizine. However a tendency
could be shown from the extracted data. Therefore,
as a consequence of this analysis of a database con-
taining the data from 92,900 patients with allergic
rhinitis, the administration of levocetirizine as mono-
therapy should be considered a primary treatment
choice for patients with moderate to severe allergic
rhinitis symptoms.
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